Plasma coagulation cascade

The plasma coagulation cascade is a highly regulated physiological process involving a series of enzymatic reactions that culminate in the formation of a fibrin clot to prevent blood loss following vascular injury (StatPearls, 2023). It is traditionally described as having three components: the extrinsic pathway initiated by tissue factor, the intrinsic pathway initiated by contact with negatively charged surfaces, and the common pathway where both converge to activate Factor X and subsequently Thrombin (NIH, 2022). Thrombin then converts soluble fibrinogen into insoluble fibrin strands, which are cross-linked to stabilize the primary platelet plug (PubMed, 2021). Dysregulation of this system is central to the pathogenesis of thromboembolic disorders like deep vein thrombosis and pulmonary embolism, as well as bleeding disorders like hemophilia (Wikipedia, 2024). Therapeutic strategies focus on modulating specific factors within the cascade—most notably Factor Xa and Thrombin—using anticoagulants to reduce the risk of stroke and myocardial infarction (StatPearls, 2023). While effective, these interventions carry a significant risk of hemorrhage, requiring careful monitoring of biomarkers like INR or aPTT (NIH, 2022).

Other names

Blood coagulation cascadeClotting cascadeCoagulation systemHemostatic cascadeCoagulation pathway

Drugs targeting the plasma coagulation cascade primarily act by inhibiting specific serine proteases such as Factor Xa or Thrombin (Factor IIa), antagonizing the hepatic synthesis of vitamin K-dependent clotting factors (Factors II, VII, IX, and X), or potentiating the activity of endogenous anticoagulants like antithrombin III to prevent fibrin formation (StatPearls, 2023; PubMed, 2021).